Goldman Sachs
PRQR icon

Goldman Sachs’s ProQR Therapeutics PRQR Stock Holding History

Goldman Sachs’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-157,910
Closed -$117K – 6212
2022
Q3 		$117K Sell
157,910
-1,886
-1% -$1.51K ﹤0.01% 5650
2022
Q2 		$124K Sell
159,796
-616,139
-79% -$459K ﹤0.01% 5804
2022
Q1 		$702K Sell
775,935
-3,137,459
-80% -$10.5M ﹤0.01% 5106
2021
Q4 		$31.3M Buy
3,913,394
+481,325
+14% +$3.67M 0.01% 1730
2021
Q3 		$28.7M Buy
3,432,069
+99,499
+3% +$650K 0.01% 1730
2021
Q2 		$22.5M Buy
3,332,570
+20,063
+0.6% +$129K 0.01% 1945
2021
Q1 		$21.9M Buy
3,312,507
+21,472
+0.7% +$110K 0.01% 1861
2020
Q4 		$13.8M Sell
3,291,035
-25,802
-0.8% -$109K ﹤0.01% 2183
2020
Q3 		$15.9M Sell
3,316,837
-1,537
-0% -$8.04K ﹤0.01% 1922
2020
Q2 		$20.2M Sell
3,318,374
-3,329
-0.1% -$18K 0.01% 1681
2020
Q1 		$18.2M Sell
3,321,703
-28,489
-0.9% -$219K 0.01% 1579
2019
Q4 		$33.2M Buy
3,350,192
+28,085
+0.8% +$219K 0.01% 1452
2019
Q3 		$19.1M Sell
3,322,107
-21,215
-0.6% -$169K 0.01% 1814
2019
Q2 		$30.4M Sell
3,343,322
-187,246
-5% -$2.21M 0.01% 1522
2019
Q1 		$49M Buy
3,530,568
+124,466
+4% +$1.86M 0.01% 1141
2018
Q4 		$53.7M Buy
+3,406,102
New +$62.5M 0.02% 1036
2015
Q4 		– Sell
-11,135
Closed -$162K – 7303
2015
Q3 		$162K Sell
11,135
-138
-1% -$2.31K ﹤0.01% 6147
2015
Q2 		$188K Sell
11,273
-7,776
-41% -$146K ﹤0.01% 6197
2015
Q1 		$417K Buy
19,049
+7,779
+69% +$161K ﹤0.01% 5323
2014
Q4 		$244K Buy
+11,270
New +$171K ﹤0.01% 5981

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's PRQR Position: Q4 2022 in Review

Goldman Sachs sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 157,910 shares — an estimated $117K sold.

Goldman Sachs first reported a position in PRQR in Q4 2014 and held it in 20 quarters. The position peaked at $53.7M in Q4 2018. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

  • Goldman Sachs reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 157,910 ProQR Therapeutics shares in Q4 2022, an estimated $117K.
  • Goldman Sachs first reported a position in ProQR Therapeutics in Q4 2014 and held it in 20 quarters.
  • Goldman Sachs's ProQR Therapeutics position peaked at $53.7M in Q4 2018.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.